US EditionLung Cancer Remains At Bay Long After Immune Therapy Is Dropped
- Researchers reported on April 18 that immunotherapy can have lasting effects on lung cancer.
- Treatment stops sometimes because immune checkpoint inhibitors cause serious side effects.
- The study of nearly 2,800 patients showed longer treatment correlated with better outcomes.
- Dr. Pecci stated their study helps clinicians with complex treatment discontinuation considerations.
- The findings suggest patients can see extended disease control even after treatment ends.
Insights by Ground AI
Does this summary seem wrong?
38 Articles
38 Articles
All
Left
3
Center
9
Right
7
Some lung cancer patients may experience durable disease control even after discontinuing immunotherapy
A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control, according to findings published in Clinical Cancer Research.
Daily Journal+36 Reposted by 36 other sources
Lung Cancer Remains At Bay Long After Immune Therapy Is Dropped
Key Takeaways
·Cherokee County, United States
Read Full ArticleCoverage Details
Total News Sources38
Leaning Left3Leaning Right7Center9Last UpdatedBias Distribution47% Center
Bias Distribution
- 47% of the sources are Center
47% Center
L 16%
C 47%
R 37%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
